# StockWatch: Revolution’s Phase III Pancreatic Cancer Data Dazzles Investors, Analysts

- URL: https://theranews.net/blog/2026-04-20-stockwatch-revolutions-phase-iii-pancreatic-cancer-data-dazzles-investors-analys-f0424b/
- Published: 2026-04-20
- Type: Archive summary (AI-assisted summary of third-party reporting)
- Original outlet: genengnews
- Original report: https://www.genengnews.com/topics/cancer/stockwatch-revolutions-phase-iii-pancreatic-cancer-data-dazzles-investors-analysts/
- Topics: depression
- Publisher: TheraNews, operated by AdvancedCare USA Inc.
- Notice: Educational content, not medical, legal, billing or financial advice. Cite the original outlet, not this summary.

> In the trial’s overall (intent-to-treat) study population, daraxonrasib showed a median overall survival (OS) of 13.2 months, nearly double the 6.7 months demonstrated for standard-of-care chemotherapy, with a hazard ratio (HR) of 0.40 (p < 0.0001). Daraxonrasib also presented what Revolution called

---
![StockWatch: Revolution’s Phase III Pancreatic Cancer Data Dazzles Investors, Analysts](/uploads/news-images/stockwatch-revolution-s-phase-iii-pancreatic-canc-20260420110049.jpg)

---
*Originally reported by genengnews. [Read more](https://www.genengnews.com/topics/cancer/stockwatch-revolutions-phase-iii-pancreatic-cancer-data-dazzles-investors-analysts/)*

---

*Source: [https://www.genengnews.com/topics/cancer/stockwatch-revolutions-phase-iii-pancreatic-cancer-data-dazzles-investors-analysts/](https://www.genengnews.com/topics/cancer/stockwatch-revolutions-phase-iii-pancreatic-cancer-data-dazzles-investors-analysts/)*